Biomedical Scientist | Barts Health NHS Trust
| Dyddiad hysbysebu: | 20 Ionawr 2026 |
|---|---|
| Cyflog: | Heb ei nodi |
| Gwybodaeth ychwanegol am y cyflog: | £46,419 - £55,046 per annum |
| Oriau: | Llawn Amser |
| Dyddiad cau: | 19 Chwefror 2026 |
| Lleoliad: | London, E1 1FR |
| Cwmni: | Barts Health NHS Trust |
| Math o swydd: | Parhaol |
| Cyfeirnod swydd: | 7746742/259-7746742ESEL |
Crynodeb
Join the East and SouthEast Pathology Partnership — Exciting Career Opportunities in Cellular Pathology!
The East and SouthEast Pathology Partnership (ESP) is thrilled to announce significant new investment in our Cellular Pathology department, enabling us to expand and enhance our services to meet growing demand. As a result, we are recruiting for 17 new positions across a variety of roles within this dynamic and vital area of pathology.
If you are passionate about advancing healthcare through cutting-edge diagnostic science, and eager to work in a collaborative, innovative environment, ESP offers you a fantastic career opportunity.
The post holder is responsible for performing routine laboratory techniques in accordance with departmental standard operating procedures, ensuring accurate data recording on the Pathology LIMS system. As well as general housekeeping the individual is also expected to carry out laboratory techniques, assist clinical staff, maintain laboratory equipment, and participate in the rotation across various areas, with a primary focus on Advanced Diagnostics. The role involves quality management tasks, ensuring compliance with accreditation standards, and engaging in internal and external quality control processes. The job holder will supervise junior staff, contribute to training and development, and maintain up-to-date training records.The individual is expected to contribute to continuous improvement efforts, including corrective actions and audits, and take responsibility for managing incidents in the laboratory.
The post holder will be part of the Immunohistochemistry (IHC) team within the Advanced Diagnostics laboratory of the Cellular Pathology Department, delivering high-quality diagnostic services. This role involves performing complex IHC techniques, in-situ hybridization, and immunofluorescence to support cancer and disease detection. Additionally, the post holder will rotate into the Neuromuscular section, processing fresh muscle and nerve tissue samples.
Between 2021 and 2024 the Partnership undertook a complex transformation programme to establish a single network of laboratories, underpinned by a single Laboratory Information Management System (LIMS) and single Quality Management System (QMS).
The Partnership has a main hub laboratory at the Royal London Hospital and Essential Service Laboratories (ESL) as a minimum at the six other hospital sites served by the Partnership.The Partnership has three operational divisions:
• Blood Sciences including Haematology, Blood Transfusion and Biochemistry
• Microbiology and Virology
• Cellular Pathology and Cancer Diagnostics
The 2024/25 total operating costs across the Partnership were c. £121m per annum with a workforce establishment of circa. 860 WTE.
We strive to live by our WeCare values and are committed to promoting inclusion, where every staff member has a sense of belonging. We value our differences and fully advocate, cultivateand support an inclusive working environment.We particularly welcome applications from Black, Asian and minority ethnic candidates as they are underrepresented within the Pathology Partnership and Barts Health at this band
The full job description provides an overview of the key tasks and responsibilities of the role, and the person specification outlines the qualifications, skills, experience, and knowledge required. For both documents, please view the attachment/s below.
We reserve the right to close this vacancy prior to the advertised closing date, once a sufficient number of applications has been received and we regret that we are unable to provide notification if your application is unsuccessful.
This advert closes on Tuesday 3 Feb 2026